Neumora Therapeutics, Inc. (NMRA)
NASDAQ: NMRA · Real-Time Price · USD
10.63
-0.49 (-4.41%)
At close: Dec 24, 2024, 4:00 PM
11.16
+0.53 (4.99%)
After-hours: Dec 24, 2024, 4:17 PM EST
Neumora Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
124
Market Cap
1.72B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
GoodRx Holdings | 790.39M |
Amphastar Pharmaceuticals | 723.55M |
10x Genomics | 629.74M |
Certara | 372.80M |
Galapagos NV | 290.09M |
MannKind | 267.20M |
Arcutis Biotherapeutics | 138.71M |
ImmunityBio | 7.33M |
NMRA News
- 1 day ago - Neumora: Koastal-1 Readout For MDD Treatment Is First Study On Deck - Seeking Alpha
- 6 weeks ago - This biotech's stock could double if its treatment for major depressive disorder succeeds, says Mizuho - Market Watch
- 6 weeks ago - Neumora Therapeutics, Inc. (NMRA) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 7 weeks ago - Neumora Therapeutics to Participate in Upcoming Conferences in November - GlobeNewsWire
- 4 months ago - Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders - GlobeNewsWire
- 6 months ago - Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer's Disease Agitation - GlobeNewsWire
- 8 months ago - Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression - GlobeNewsWire